Alexa Fluor® 488 anti-mouse IFN-γ Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

E. coli-expressed, recombinant mouse IFN-γ

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions.

Concentration

0.5 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm.

Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses

Excitation Laser

Blue Laser (488 nm)

Application Notes

ELISA^1-4,11,14 or ELISPOT⁵ Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry^7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization^1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections^6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
7. Ferrick D, et al. 1995. Nature 373:255. (FC)
8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)

Product Citations

1. Dölz M, et al. 2022. iScience. 25:105372. PubMed
2. Nanishi E, et al. 2023. NPJ Vaccines. 8:18. PubMed
3. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
4. Arce Vargas F et al. 2018. Cancer cell. 33(4):649-663 . PubMed
5. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
6. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
7. Fumagalli V, et al. 2020. J Exp Med. :217. PubMed
8. Lucas B, et al. 2020. Nat Commun. 11:2198. PubMed
9. Moulin M, et al. 2017. Cell Mol Life Sci. 10.1007/s00018-017-2583-0. PubMed
10. Li A, et al. 2020. J Virol. 94:00:00. PubMed
11. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
12. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
13. Xiao S, et al. 2020. Cell Reports. 32(2):107892. PubMed
14. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
15. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
16. Śledzińska A, et al. 2020. Immunity. 52(1):151-166.e6.. PubMed
17. Meyer Zu Horste G et al. 2018. Immunity. 48(3):556-569 . PubMed
18. von Roemeling CA, et al. 2020. Nat Commun. 11:1508. PubMed
19. Dai K, et al. 2015. J Leukoc Biol. 98: 1071 - 1080. PubMed
20. Younes AI, et al. 2021. Transl Oncol. 14:100983. PubMed
21. Nanishi E, et al. 2022. Commun Biol. 5:790. PubMed
22. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
23. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
24. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
25. Sema Kurtulus et al. 2018. Immunity. 50(1):181-194 . PubMed
26. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
27. Mykkänen O, et al. 2014. PLoS One. 9:114790. PubMed
28. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
29. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
30. Han H, et al. 2020. Cancer Cell. 36(5):483-497.e15.. PubMed

RRID

AB_493312 (BioLegend Cat. No. 505815)
AB_493312 (BioLegend Cat. No. 505813)

Antigen Details

Structure

Cytokine; dimer; 40-80 kD (Mammalian)

Bioactivity

Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs

Cell Sources

CD8⁺ and CD4⁺ T cells, NK cells

Cell Targets

T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts

Receptors

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

Cell Type

Tregs

Biology Area

Cell Biology, Immunology, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation

Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone

Gene ID

15978 View all products for this Gene ID

UniProt

View information about IFN-gamma on UniProt.org

Related Protocols

• Surface and Intracellular Cytokine Staining for Flow Cytometry - Video
• Intracellular Flow Cytometry Staining Protocol

Other Formats